- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04392973
FAvipiravir and HydroxyChloroquine Combination Therapy (FACCT)
A Trial of Favipiravir and Hydroxychloroquine Combination in Adults Hospitalized With Moderate and Severe Covid-19
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In this trial, the investigators want to evaluate the efficacy of the combination of Favipiravir and Hydroxychloroquine as potential therapy for moderate and severe cases with COVID -19. Favipiravir which is a new type of RNA-dependent RNA polymerase (RdRp) inhibitor has activity against influenza virus, and Hydroxychloroquine, an analogue of chloroquine, has a clinical safety profile better than that of chloroquine and allows higher daily dose, Chloroquine is a widely used antimalarial that was found to be a potential broad-spectrum antiviral.
There is an urgent need to explore therapeutic options for SARS-CoV-2 in order to face the pandemic. The selected combination was based on limited evidence clinically and in vitro on the efficacy of the Favipiravir and Hydroxychloroquine in SARS-CoV-2. The two medications were listed in many guidelines as treatment options and ongoing trials assessing their efficacy and safety. Thus, the investigators want to prove the effectiveness of the combination as therapy.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Al Madīnah, Saudi Arabia
- AlMadina General Hospital
-
Al-Qatif, Saudi Arabia
- Al-Qatif Central Hospital
-
Dammam, Saudi Arabia
- Imam Abdulrahman Al Faisal Hospital - Dammam
-
Jeddah, Saudi Arabia
- King Abdulaziz Medical City
-
Mecca, Saudi Arabia
- King Abdulaziz Hospital - Makkah
-
Riyadh, Saudi Arabia, 11426
- King Abdulaziz Medical City, National Guard Health Affairs
-
Riyadh, Saudi Arabia
- Imam Abdulrahman Alfaisal Hospital
-
-
Eastern Region
-
Hasa, Eastern Region, Saudi Arabia
- King Abdulaziz Hospital - Al Ahsa
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Should be at least 18 years of age
- Male or nonpregnant female,
- Diagnosed with COVID-19 by PCR confirmed SARS-coV-2 viral infection.
- Able to sign the consent form and agree to clinical samples collection (or their legal surrogates if subjects are or become unable to make informed decisions).
- Moderate or Severe COVID-19, defined as oxygen saturation (Sao2) of 94% or less while they were breathing ambient air or significant clinical symptoms with Chest X ray changes that require hospital admission.
- patients had to be enrolled within 10 days of disease onset
Exclusion Criteria:
- Patients who are pregnant or breastfeeding.
- Will be transferred to a non-study site hospital or expected to be discharged within 72 hours.
- Known sensitivity/allergy to hydroxychloroquine or Favipiravir
- Current use of hydroxychloroquine for another indication
- Prior diagnosis of retinopathy
- Prior diagnosis of glucose-6-phosphate dehydrogenase (G6PD) deficiency
- Major comorbidities increasing the risk of study drug including: i. Hematologic malignancy, ii. Advanced (stage 4-5) chronic kidney disease or dialysis therapy, iii. Known history of ventricular arrhythmias, iv. Current use of drugs that prolong the QT interval, Severe liver damage (Child-Pugh score ≥ C, AST> 5 times the upper limit), HIV.
- The investigator believes that participating in the trial is not in the best interests of the patient, or the investigator considers unsuitable for enrollment (such as unpredictable risks or subject compliance issues).
- Clinical prognostic non-survival, palliative care, or in deep coma and no have response to supportive treatment within three hours of admission.
- Patient with irregular rhythm
- Patient with a history of heart attack (myocardial infarction)
- Patient with a family history of sudden death from heart attack before the age of 50
- Take other drugs that can cause prolonged QT interval
- Patient who is receiving immunosuppressive therapy (cyclosporin) which cannot be switched to another agent or adjusted while using the investigational drug
- Gout/history of Gout or hyperuricemia (above the ULN), hereditary xanthinuria or xanthine calculi of the urinary tract.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention
Combination therapy Favipiravir (10 days) + Hydroxychloroquine(5 days)
|
Route of Administration: Oral (or through Nasogastric tube) Dose: Favipiravir: Administer 1800 mg (9 tablets) by mouth twice daily for one day, followed by 800mg (4 tablets) twice daily (total days of therapy is 10 days or till hospital discharge) Hydroxychloroquine (400mg) twice daily on day 1; for days 2-5 (200mg) twice daily.
Other Names:
|
No Intervention: Control
Standard of Care Treatment for COVID-19 Infection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Improvement
Time Frame: 28 days
|
The primary endpoint is the time to clinical improvement, defined as the time from the randomization to an improvement of two points (from the status at randomization) on a seven-category ordinal scale or live discharge from the hospital, whichever came first.
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Viral shedding
Time Frame: 28 days
|
PCR test negative conversion days from positive to negative.
|
28 days
|
Collaborators and Investigators
Investigators
- Study Director: Ahmad Alaskar, KAIMRC
Publications and helpful links
General Publications
- Bosaeed M, Mahmoud E, Alharbi A, Altayib H, Albayat H, Alharbi F, Ghalilah K, Al Arfaj A, AlJishi J, Alarfaj A, Alqahtani H, Almutairi BM, Almaghaslah M, Alyahya NM, Bawazir A, AlEisa S, Alsaedy A, Bouchama A, Alharbi M, AlShamrani M, Al Johani S, Aljeraisy M, Alzahrani M, Althaqafi AO, Almarhabi H, Alotaibi A, Alqahtani N, Arabi YM, Aldibasi OS, Alaskar A. Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID-19 (FACCT Trial): An Open-Label, Multicenter, Randomized, Controlled Trial. Infect Dis Ther. 2021 Dec;10(4):2291-2307. doi: 10.1007/s40121-021-00496-6. Epub 2021 Jul 28.
- Bosaeed M, Mahmoud E, Hussein M, Alharbi A, Alsaedy A, Alothman A, Aljeraisy M, Alqahtani H, Nashabat M, Almutairi B, Almaghaslah M, Aldibasi O, AlJohani S, Bouchama A, Arabi Y, Alaskar A. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020 Oct 31;21(1):904. doi: 10.1186/s13063-020-04825-x.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- COVID-19
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antirheumatic Agents
- Antiprotozoal Agents
- Antiparasitic Agents
- Antimalarials
- Favipiravir
- Hydroxychloroquine
Other Study ID Numbers
- RC20/174
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID19
-
Anavasi DiagnosticsNot yet recruiting
-
Ain Shams UniversityRecruiting
-
Israel Institute for Biological Research (IIBR)Completed
-
Colgate PalmoliveCompleted
-
Christian von BuchwaldCompleted
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActive, not recruiting
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichEnrolling by invitation
-
Alexandria UniversityCompleted
Clinical Trials on Favipiravir and Hydroxychloroquine
-
Ministry of Health, TurkeyIstanbul University; Ankara Training and Research Hospital; Prof. Dr. Cemil Tascıoglu... and other collaboratorsActive, not recruitingCOVID-19 | Sars-CoV2Turkey
-
Health Institutes of TurkeyCompleted
-
Afyonkarahisar Health Sciences UniversityNeuTec PharmaCompleted
-
Institut National de la Santé Et de la Recherche...FUJIFILM Toyama Chemical Co., Ltd.RecruitingInfectious Disease | PharmacologyFrance
-
Appili Therapeutics Inc.University Health Network, Toronto; Sunnybrook Health Sciences Centre; University... and other collaboratorsTerminated
-
MDVI, LLCMediVector, Inc.CompletedInfluenzaUnited States, Russian Federation, Turkey, Spain, Belgium, Hungary, South Africa, Bulgaria, Ukraine, Poland, Netherlands, Australia, New Zealand, Sweden
-
MDVI, LLCMediVector, Inc.CompletedInfluenzaUnited States, Canada, Brazil, Mexico, Colombia, Argentina, Peru, Puerto Rico, Guatemala, Dominican Republic, El Salvador
-
Royal College of Surgeons in Ireland - Medical...Ebrahim Khalil Kanoo Community Medical Center; Hereditary blood Disorder Centre... and other collaboratorsCompleted
-
Shahid Beheshti University of Medical SciencesUnknown
-
Peking University First HospitalUnknown